Calgary, Alberta--(Newsfile Corp. - September 13, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Mr. Thomas Abraham, CA as President, PreCerv Inc.
Mr. Abraham has more than 25 years of financing, business development, and governance and risk management experience in a broad range of roles encompassing private equity investment transactions, including sales and distribution of alternative investments, in Toronto, New York, Abu Dhabi, Singapore, Kuala Lumpur, and Glasgow, Scotland. Most recently, Mr. Abraham was the Chief Executive Officer of the Financial Services Professional Board (FSPB), where he was responsible for all business development with local and international bodies, including the oversight of all programs and standards setting activities of FSPB to achieve its mission and objectives. Mr. Abraham is a member of the Institute of Corporate Directors Canada, a Committee member of TC309, Standards Council of Canada, and the Institute of Chartered Accountants of Scotland. He holds a bachelor's degree in Accountancy from London Metropolitan University, U.K.
"ACP-01's safety and efficacy profile is very impressive, and it is equally promising to combine it NCP to treat conditions of the central and peripheral nervous system," stated Thomas Abraham. "I very much look forward to financing and leading the team that will study, develop and commercialize NCP-01 and ACP-01 in the neuronal field," Mr. Abraham said.
"Mr. Abraham's finance and business relationships spans decades in Toronto, New York, the UAE, Singapore, and Malaysia. He is perfectly suited to lead, finance and build PreCerv into a great company focused on treating conditions of the central and peripheral nervous system for Hemostemix shareholders' benefit," stated Thomas Smeenk, CEO.
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families. For more information, please visit www.hemostemix.com.
ABOUT PreCerv Inc.
PreCerv Inc. is a wholly owned subsidiary of Hemostemix Inc. PreCerv obtained from Hemostemix a global field of use license to NCP-01 and ACP-01, and its autologous stem cell technologies, to treat conditions of the central and peripheral nervous system, including but not limited to neuropathic pain syndromes; traumatic spinal cord injury, peripheral nerve injury; rare diseases including syringomyelia and age-related macular degeneration (ARMD). NCP-01 are autologous neuronal cell precursors derived from the patient's blood.
For further information, please contact:
Thomas Smeenk, President, CEO & Co-Founder
EM: firstname.lastname@example.org PH: 905-580-4170
Thomas Abraham, President, PreCerv Inc., EM: email@example.com PH: 647-461-7169
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the lead product ACP-01, NCP-01, and the commercialization of ACP-01 and NCP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis mayface; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/136904